1. 1.5 Billion Won in Research Funding Secured Over Three Years
2. "Full-Scale Commercialization of Targeted Anticancer Drugs for Refractory Cancers"

Korea University Guro Hospital announced on February 3 that Jae Hong Seo, Professor of Oncology, has been selected for the "2026 Deep Science Startup Activation Support Project" organized by the Ministry of Science and ICT.

Jae Hong Seo, Professor of Oncology at Korea University Guro Hospital. Korea University Guro Hospital

Jae Hong Seo, Professor of Oncology at Korea University Guro Hospital. Korea University Guro Hospital

View original image

The Deep Science Startup Activation Support Project is a government support program designed to connect advanced scientific and technological research outcomes with startup creation and market entry. Professor Seo formed a consortium with the Darae Strategic Commercialization Center, focusing on modular small molecule-drug conjugate (SMDC)-based targeted anticancer drug technology for refractory cancers, and completed the first phase of the project last year. This year, he has been selected again for the second phase of the project.


The research team will receive a total of 1.5 billion won in research funding over the next three years to advance the development of new targeted anticancer drug candidates for refractory cancers and to establish a foundation for commercialization. Professor Seo plans to launch a startup as founder and Chief Technology Officer (CTO) in the first half of this year. For the role of professional manager, Kim Joungho, former Executive Director at GC Genome, will be recruited as Chief Executive Officer (CEO), with the aim of simultaneously pursuing research and development as well as commercialization.


Professor Seo's research team has set global technology transfer as its top priority for this technology and plans to expand multiple pipelines.


Previously, Professor Seo accumulated research achievements in the field of anticancer drug development through numerous patents and international academic publications. Most recently, he identified the anticancer effect of pitavastatin, a component used in hyperlipidemia treatments, against triple-negative breast cancer. He also discovered a candidate substance (HVH-2930) that inhibits resistance to targeted therapies in HER2-positive breast cancer, continuing his research on new drug candidates focused on refractory cancers.



Professor Seo stated, "I have long been dedicated to developing innovative targeted anticancer drugs for refractory cancers that can overcome the limitations of existing anticancer drugs, such as resistance, recurrence, and metastasis. The modular small molecule-drug conjugate technology platform is expected to facilitate the expansion into various pipelines, enabling the discovery of multiple candidate substances and entry into clinical trials."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing